Guidelines of the Polish Society of Laboratory Diagnosticsand the Polish Lipid Association on laboratory diagnosticsof lipid metabolism disorders. 2024 DOI
Bogdan Solnica, Grażyna Sygitowicz, Dariusz Sitkiewicz

et al.

Diagnostyka Laboratoryjna, Journal Year: 2024, Volume and Issue: 60(1), P. 1 - 24

Published: March 25, 2024

Lipid disorders are the most common (even 70%) and worst monitored cardiovascular risk factor (only 1/4 of patients in Poland CEE countries on low-density lipoprotein cholesterol (LDL-C) goal). To improve this, clear simple diagnostic criteria should be introduced for all components lipid profile. These updated guidelines two main scientific societies area – Polish Society Laboratory Diagnostics (PSLD) Association (PoLA), which, comparison to those from 2020, introduce few important changes recommendations (two targets, new LDL-C measurements, calculations goals triglycerides, remnants small dense LDL) that help practitioners early with diagnosis effective monitoring (after therapy initiation), consequence avoid first recurrent events.

Language: Английский

Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association DOI Creative Commons
Maciej Banach, Stanisław Surma, Agnieszka Kapłon‐Cieślicka

et al.

Archives of Medical Science, Journal Year: 2023, Volume and Issue: 20(1), P. 28 - 42

Published: Nov. 26, 2023

Lipid disorders, primarily hypercholesterolemia, are the most common cardiovascular (CV) risk factor in Poland (this applies even 3/4 of people). The low-density lipoprotein cholesterol (LDL-C) serum level is basic lipid parameter that should be measured to determine CV and determines aim target lipid-lowering treatment (LLT). Lipid-lowering improves prognosis prolongs life both primary secondary prevention. Despite availability effective drugs solid data on their beneficial effects, LDL-C control highly insufficient. This related, among other things, physician inertia patients’ fear side effects. development lipidology has made available with a good safety profile enabling personalisation therapy. Pitavastatin, third potent statin, characterised by lower muscle complications new cases diabetes due its being metabolised differently. Thus, pitavastatin very therapeutic option patients at high or existing diabetes, risk. expert opinion paper attempts recommendation place possibility using disorders.

Language: Английский

Citations

5
A Nation-Wide Evaluation of Suboptimal Lipid-Lowering Treatment Patterns Among Patients Undergoing Intervention for Acute Coronary Syndrome in Hungary DOI Open Access
G Nagy, László Márk,

Andrea Gerencser

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(21), P. 6562 - 6562

Published: Oct. 31, 2024

: A significant gap exists between guideline recommendations and everyday practice. Stringent treatment is needed for vulnerable patients with acute coronary syndrome (ACS).

Language: Английский

Citations

1
Targeting PDGF/PDGFR Signaling Pathway by microRNA, lncRNA, and circRNA for Therapy of Vascular Diseases: A Narrow Review DOI Creative Commons

Chaonan Ma,

Shan-Rui Shi,

Xueying Zhang

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(11), P. 1446 - 1446

Published: Nov. 14, 2024

Despite the significant progress in diagnostic and therapeutic strategies, vascular diseases, such as cardiovascular diseases (CVDs) respiratory still cannot be successfully eliminated. Vascular cells play a key role maintaining homeostasis. Notably, variety of produce secrete platelet-derived growth factors (PDGFs), which promote mitosis induce division, proliferation, migration including smooth muscle (SMCs), aortic SMCs, endothelial cells, airway SMCs. Therefore, PDGF/PDGR receptor signaling pathways vital roles regulating homeostasis blood vessels onset development CVDs, atherosclerosis, asthma pulmonary arterial hypertension. Recently, accumulating evidence has demonstrated that microRNA, long-chain non-coding RNA, circular RNA are involved regulation PDGF/PDGFR through competitive interactions with target mRNAs, contributing to occurrence above-mentioned diseases. These novel findings useful for laboratory research clinical studies. The aim this article is conclude recent progresses field, particular mechanisms action these RNAs remodeling, providing potential strategies diagnosis, prevention, treatment vascular-dysfunction-related particularly CVDs

Language: Английский

Citations

1
Summary of 2023 and the biggest challenges for the “Archives of Medical Science” on its 20th Anniversary DOI Creative Commons
Maciej Banach

Archives of Medical Science, Journal Year: 2024, Volume and Issue: 20(1), P. 1 - 7

Published: Jan. 31, 2024

We are in the year of 20 th Anniversary Archives Medical Science (AMS).I remember when 2004, just 2 years after my graduation, I approached largest Polish publishing house -Termedia, and suggested starting/launching an international, wide-scope, open-access scientific journal.The discussions were not easy, but finally was able to convince Publishers start a completely new department Termedia Publishing House related development journals, which is now one Central Eastern Europe with almost 60 journals.Within this summary 2023 for journal would like present parametric data, also suggesting new, innovative indicators that hopefully inspire other Editors real potential papers published given year.Let's TOP 10 Most Cited Papers 2022 based on citations from Web by Clarivate Dimensions Altmetric (Table I).Year obviously means those (as well as 2021) will play most important role calculations impact factor (IF2023) (to be released June 2024).For these suggest indicator called time corrected index (TcCI) considers collecting and, due frequency publication (6 issues per year), multipliers 1.0 (for 1/2022 issue chance get highest number longest since publication) through 1.2 2/2022 issue), 1.4 3/2022 1.6 4/2022 1.8 5/2022 issue) 2.0 6/2022 issue).If we look at areas authors citations, first place definitely guidelines societies metabolic syndrome [1], top 10, can find next 4 area cardiovascular diseases [2-5], paper statins lung cancer [6], presenting genetic biomarkers Alzheimer disease (AD) [7], has been very hot topic several now, two covering 9], critically health status its socio-economic covariates older population Poland PolSenior2 survey [10].I am happy some prepared within wide international research team, all abovementioned deserve huge congratulations distinctions.

Language: Английский

Citations

0
Guidelines of the Polish Society of Laboratory Diagnosticsand the Polish Lipid Association on laboratory diagnosticsof lipid metabolism disorders. 2024 DOI
Bogdan Solnica, Grażyna Sygitowicz, Dariusz Sitkiewicz

et al.

Diagnostyka Laboratoryjna, Journal Year: 2024, Volume and Issue: 60(1), P. 1 - 24

Published: March 25, 2024

Lipid disorders are the most common (even 70%) and worst monitored cardiovascular risk factor (only 1/4 of patients in Poland CEE countries on low-density lipoprotein cholesterol (LDL-C) goal). To improve this, clear simple diagnostic criteria should be introduced for all components lipid profile. These updated guidelines two main scientific societies area – Polish Society Laboratory Diagnostics (PSLD) Association (PoLA), which, comparison to those from 2020, introduce few important changes recommendations (two targets, new LDL-C measurements, calculations goals triglycerides, remnants small dense LDL) that help practitioners early with diagnosis effective monitoring (after therapy initiation), consequence avoid first recurrent events.

Language: Английский

Citations

0